Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against Covid-19.
Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals.
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma.
One promising way to treat diabetes is with transplanted islet cells that produce insulin when blood sugar levels get too low.
A study published in the Jan 16 edition of the New England Journal of Medicine suggests that erythropoietin treatment may not provide neuroprotection for extremely premature babies.
The hormone erythropoietin (Epo) is a well-known doping substance that has a long history of abuse in endurance sports, such as cycling. In addition to promoting red blood cell production (erythropoiesis), which improves the oxygen supply in the organism, Epo also protects nerve cells from cell death.
The kidney is an organ not only for excreting body waste by urine but also for maintaining body homeostasis in close cooperation with other organs.
The Dove Medical Press journal, Nature and Science of Sleep, has published a study that highlights the potential use of blood biomarkers as a diagnostic tool for obstructive sleep apnea.
It's the late 1970s, and a man with an unexplained high hemoglobin level (Hb) is referred to Namsos Hospital north of Trondheim, Norway. It turns out that four members of his family have the same condition. Doctor Kjell Kanelønning is the physician who treats the family.
Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.
Erythropoietin helps to protect and repair vulnerable brains though it remains a mystery how the anemia drug does so.
A newly-discovered hereditary mutation is responsible for an increased production of erythropoietin (EPO) in the blood.
A new discovery from the University of Virginia School of Medicine has revealed an unknown clockwork mechanism within the body that controls the creation of oxygen-carrying red blood cells.
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
UT Southwestern Medical Center pediatric researchers have harnessed an analytical tool used to predict the weather to evaluate the effectiveness of therapies to reduce brain injury in newborns who suffer oxygen deprivation during birth.
Mary Elizabeth Hartnett, MD, and colleagues at the John A. Moran Center and Department of Pediatrics at the University of Utah and Children's Hospital of Wisconsin, were looking for a way to tease apart the effects of preeclampsia on the risk of developing retinopathy of prematurity (ROP), an eye disease found in premature infants. Their results, and the model they developed, were published February 14, 2017, in Scientific Reports.
Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
A study has found that EPO (erythropoietin) - best known as a performance-enhancing drug in sport - may improve cognitive functioning in patients suffering from bipolar disorder or depression.